All Posts By

Smartkarma Newswire

Xiaomi’s Stock Price Skyrockets to 19.16 HKD, Marking a Stunning 9.36% Increase

By | Market Movers

Xiaomi (1810)

19.16 HKD +1.64 (+9.36%) Volume: 413.67M

Xiaomi’s stock price soars to 19.16 HKD, marking a significant trading session increase of +9.36% and a robust YTD growth of +21.67%, backed by a hefty trading volume of 413.67M, underlining its strong market performance.


Latest developments on Xiaomi

Xiaomi Corp has been making waves in the market recently with its strong performance in the second quarter of 2024. The company’s revenue has surpassed estimates, fueled by the successful launch of its SU7 electric car in China. Despite incurring losses in the electric vehicle sector to compete with industry giant Tesla, Xiaomi’s shares have rallied on the back of solid Q2 revenues. With sales growing at the fastest rate since 2021, Xiaomi is determined to establish itself in the big leagues of the automotive industry. The company’s auto business and smartphone sales have driven a 32% increase in Q2 revenue, reaching a record-breaking $12.5 billion. Xiaomi’s foray into the EV market has proven fruitful, pulling in an impressive $900 million in revenue from its first electric vehicle. As Xiaomi continues to expand its presence in the auto sector, investors are closely watching the stock price movements, which have been on an upward trend following the company’s strong performance.


Xiaomi on Smartkarma

Analysts on Smartkarma have provided coverage on Xiaomi Corp, with a mix of bullish and bearish sentiments. Tech Supply Chain Tracker highlighted the growth and competition in the semiconductor industry, mentioning strategic moves by companies like Xiaomi to stay ahead. On the other hand, Ming Lu expressed a bullish sentiment, noting a significant revenue increase and the potential for profit in the electric vehicle sector for Xiaomi.

Furthermore, Ming Lu also reported on Xiaomi’s market share growth and high shipments in 2Q24, projecting a 35% upside potential for the stock by the end of 2024. Overall, analysts like Devi Subhakesan and Ming Lu have been closely monitoring Xiaomi’s performance in various markets, showcasing the company’s strong sales in both China and India, as well as its global market share expansion.


A look at Xiaomi Smart Scores

FactorScoreMagnitude
Value3
Dividend1
Growth3
Resilience5
Momentum5
OVERALL SMART SCORE3.4

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Xiaomi Corp has a mixed long-term outlook. While the company scores well in resilience and momentum, with a score of 5 for both factors, it falls short in terms of dividend, with a score of 1. This suggests that Xiaomi may not be a top choice for investors looking for consistent dividend payouts. However, the company scores moderately in terms of value and growth, with scores of 3 for both factors, indicating that there is potential for Xiaomi to increase in value over time and continue to grow its business.

Xiaomi Corporation is a manufacturer of communication equipment and parts, known for its production and sale of mobile phones, smart phone software, set-top boxes, and related accessories. With a global market presence, Xiaomi has shown resilience and momentum in its operations, indicating a strong ability to withstand challenges and maintain a positive growth trajectory. While the company may not offer high dividend returns, its focus on value and growth suggests that Xiaomi may still be a promising investment option for those looking for long-term potential in the technology sector.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

Industrial and Commercial Bank of China’s Stock Price Soars to 4.68 HKD, Marking a Promising 0.86% Increase

By | Market Movers

Industrial and Commercial Bank of China (1398)

4.68 HKD +0.04 (+0.86%) Volume: 269.74M

Industrial and Commercial Bank of China’s stock price is currently performing well, standing at 4.68 HKD with a positive trading session change of +0.86%. With a substantial trading volume of 269.74M and an impressive YTD percentage change of +22.51%, ICBC (1398) continues to show strong stock market performance.


Latest developments on Industrial and Commercial Bank of China

ICBC (H) has recently shared important safety tips for drivers, parents, and caregivers as children head back to school. This initiative comes in light of the alarming statistic that nearly 360 children are injured by vehicles every year in British Columbia while on their way to school. These safety tips aim to raise awareness and prevent accidents, which could potentially impact the company’s stock price as investors monitor the impact of safety campaigns on the public perception of ICBC (H) as a responsible and socially conscious entity.


Industrial and Commercial Bank of China on Smartkarma

Analyst coverage of ICBC (H) on Smartkarma by Travis Lundy has shown a bullish sentiment. In the report “HK Connect SOUTHBOUND Flows (To 5 Jul 2024)”, it was highlighted that SOE Banks and SOE Energy names dominated the net buy list, with national team SOUTHBOUND being a net buyer. The report mentioned that there has been serious national team buying of banks and energy, possibly ahead of shareholder return policy changes. Despite this, valuations were deemed acceptable, and the overall sentiment was positive towards ICBC (H).

In another report by Travis Lundy titled “A/H Premium Tracker (To 3 May 2024): Minimal Moves in 2-Day Week”, the analyst noted mixed AH Premia performance with As and Hs outperforming in different scenarios. The report also mentioned consecutive net buying streaks by SOUTHBOUND and big inflows from NORTHBOUND, indicating strong investor interest in ICBC (H). Overall, the direction of AH Premia was predicted to be down, but with potential for growth based on market movements. The analysis provided valuable insights for investors looking to understand the market dynamics surrounding ICBC (H).


A look at Industrial and Commercial Bank of China Smart Scores

FactorScoreMagnitude
Value4
Dividend5
Growth4
Resilience3
Momentum5
OVERALL SMART SCORE4.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Industrial and Commercial Bank of China Limited (ICBC) is showing a positive long-term outlook based on the Smartkarma Smart Scores. With high scores in Dividend and Momentum, ICBC is positioned well for growth and stability in the future. The company’s strong dividend score indicates a solid return for investors, while its momentum score suggests a positive trend in the market.

Additionally, ICBC scores well in Value and Growth, further solidifying its position as a strong player in the banking industry. While the Resilience score is slightly lower, indicating some potential areas of improvement, overall, ICBC’s performance in key areas bodes well for its long-term success. As a provider of banking services to individuals, enterprises, and other clients, ICBC is poised to continue its positive trajectory in the market.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

Agricultural Bank of China’s stock price soars to 3.59 HKD, marking a bullish 1.99% increase

By | Market Movers

Agricultural Bank of China (1288)

3.59 HKD +0.07 (+1.99%) Volume: 111.97M

Agricultural Bank of China’s stock price is currently at 3.59 HKD, showcasing a promising +1.99% change this trading session and a significant +19.27% YTD growth. With a considerable trading volume of 111.97M, it continues to offer an attractive investment opportunity in the Chinese banking sector.


Latest developments on Agricultural Bank of China

Today, Agricultural Bank of China’s stock price is experiencing movements following a series of key events. The bank recently listed new notes on NASDAQ Dubai and redeemed billion bonds, attracting investor attention. Amidst a frenzied hunt for yield, China banks, including Agricultural Bank of China, emerged as surprise winners. Additionally, the bank scheduled a crucial board meeting and an extraordinary general meeting for 2024, where a new executive director is set to be nominated. These developments have contributed to the fluctuation in Agricultural Bank of China’s stock price today.


Agricultural Bank of China on Smartkarma

Analyst coverage of Agricultural Bank Of China on Smartkarma by Travis Lundy indicates a bullish sentiment. In his report titled “HK Connect SOUTHBOUND Flows (To 28 June 2024); Still a Net Buy, but Less Strong. Financials Dominate”, Lundy highlights the positive trend of SOUTHBOUND being a net buyer for the past 20 weeks. Despite some uncertainties surrounding factors like expected dividend tax removal and policy changes, valuations are deemed acceptable. Banks, including Agricultural Bank Of China, were identified as a big buy in the report.

With a focus on financials dominating the investment landscape, Lundy’s analysis suggests that Agricultural Bank Of China may continue to see inflows from both national team buying and other sources. The report emphasizes the importance of policy changes and shareholder return KPIs for SOE CEOs in influencing the market dynamics. Overall, the outlook for Agricultural Bank Of China remains positive based on the insights provided by Travis Lundy on Smartkarma.


A look at Agricultural Bank of China Smart Scores

FactorScoreMagnitude
Value4
Dividend5
Growth4
Resilience2
Momentum5
OVERALL SMART SCORE4.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Agricultural Bank Of China has a positive long-term outlook. The company scores high in Dividend and Momentum, indicating strong performance in these areas. With a solid Value and Growth score as well, Agricultural Bank Of China is positioned well for future growth and stability. However, the company’s Resilience score is lower, suggesting some potential risk factors to consider.

Agricultural Bank Of China Limited offers a wide range of commercial banking services, including deposit, loan, settlement, currency trading, and treasury bill underwriting. With a strong focus on dividends and momentum, the company is showing promising signs for investors. While there are some resilience concerns, overall, Agricultural Bank Of China‘s performance in key areas bodes well for its future prospects in the banking industry.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

Bank of China’s Stock Price Sees Encouraging Uptick, Climbing to 3.58 HKD with a Positive 1.13% Shift

By | Market Movers

Bank of China (3988)

3.58 HKD +0.04 (+1.13%) Volume: 177.31M

Bank of China’s stock price stands at 3.58 HKD, showcasing a promising upward trend with a trading session increase of +1.13%, a robust trading volume of 177.31M, and an impressive YTD percentage change of +18.79%, reflecting the bank’s positive market performance.


Latest developments on Bank of China

Today, Bank of China Ltd (H) stock price experienced significant movements following the news that PwC, one of its major clients, has lost the bank amid a regulatory probe. This development has raised concerns among investors and analysts, leading to increased volatility in the stock price. The market is closely monitoring the situation as more details about the regulatory probe and its potential impact on Bank of China Ltd (H) emerge. Stay tuned for further updates on this developing story.


A look at Bank of China Smart Scores

FactorScoreMagnitude
Value4
Dividend5
Growth4
Resilience2
Momentum5
OVERALL SMART SCORE4.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Bank Of China Ltd (H) is showing strong potential for long-term growth, with high scores in Dividend and Momentum according to Smartkarma Smart Scores. This indicates that the company is likely to continue providing attractive dividends to shareholders and has positive momentum in its stock performance. Additionally, the Value and Growth scores suggest that the company is trading at a reasonable price and has solid potential for future expansion. However, the lower score in Resilience may indicate some vulnerability to market fluctuations or economic downturns.

Overall, Bank Of China Ltd (H) appears to be a solid investment option for those looking for a company with strong dividend payouts and positive momentum in its stock performance. With a diverse range of financial services offered to customers worldwide, the company is well-positioned to capitalize on opportunities for growth and profitability in the banking sector. Investors may want to keep an eye on how the company addresses any potential resilience issues to ensure long-term stability and success.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

Beijing Wantai Biological Phar (603392) Earnings: 1H Net Income Surges to 260.5M Yuan

By | Earnings Alerts
  • Net Income: Wantai Bio reported a net income of 260.5 million yuan for the first half of the year.
  • Revenue: The company’s revenue for the period was 1.37 billion yuan.
  • R&D Expenses: Research and development expenses amounted to 479.9 million yuan.
  • Analyst Recommendations: Wantai Bio received 6 buy recommendations, 1 hold, and 1 sell rating from analysts.

Beijing Wantai Biological Phar on Smartkarma

On Smartkarma, independent analyst Tina Banerjee has published research on Beijing Wantai Biological Phar. In her report titled “Beijing Wantai Biological (603392 CH): Struggling to Make a Mark in Murky China HPV Vaccine Market,” she highlights the challenges facing the company. Beijing Wantai is expecting a significant decline in net profit in 2023, mainly attributed to intense competition in the China HPV vaccine market. With more players entering the market, competition is set to further escalate, posing challenges for Beijing Wantai to establish a strong foothold.

Tina Banerjee‘s analysis suggests that Beijing Wantai Biological Phar is facing tough competition in the highly competitive China HPV vaccine market. Despite being an early mover in domestically developed nonavalent HPV vaccines, the company is anticipated to face competition from at least three more players entering the market soon. This increasing competition in the segment where Beijing Wantai lacks presence might pose obstacles to its growth and market positioning in the evolving landscape of the Chinese HPV vaccine market.


A look at Beijing Wantai Biological Phar Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth3
Resilience5
Momentum5
OVERALL SMART SCORE3.4

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is expected to have a positive long-term outlook based on the Smartkarma Smart Scores. With a solid resilience score of 5, the company is deemed to be well-prepared to weather uncertainties and shocks in the market, showcasing its stability and strength. Additionally, a momentum score of 5 indicates strong positive momentum in the company’s stock performance, suggesting a bullish trend that investors might find attractive.

Furthermore, while the growth score of 3 reflects moderate growth prospects for Beijing Wantai Biological Pharmacy, the company scores 2 out of 5 for both value and dividend factors. This indicates that investors might not find the stock particularly undervalued or attractive for dividend income. Overall, with its strengths in resilience and momentum, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. shows promise for the future.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

Steady STI Trading Reflects Smooth Economic Landing Focus

By | Press Coverage

Excerpt: … update :True strength and potential emerge Suntec REIT: DBS – Suntec REIT update : Standing firm in Singapore CapitaLand Ascott Trust: DBS – Capitaland Ascott Trust update : Awaiting the Olympics leap Company interviews Lendlease Global: Smartkarma …

I3investor β€’ (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now

7-Eleven deal talk reflects allure of Japan’s convenience stores – Reed Stevenson & Supriya Singh 5.77

By | Press Coverage

Excerpt: The buyout offer has β€œhighlighted Seven & i’s significant undervaluation versus global peers,” said Mark Chadwick, an analyst who publishes on Smartkarma.

I3investor β€’ (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now

7-Eleven deal talk reflects allure of Japan’s convenience stores

By | Press Coverage

Excerpt: The buyout offer has β€œhighlighted Seven & i’s significant undervaluation versus global peers,” said Mark Chadwick, an analyst who publishes on Smartkarma.

Supriya Singh β€’ (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now

Xero Ltd (XRO) Earnings: Projected Operating Expense to Revenue Ratio Steady at 73% for FY25

By | Earnings Alerts
  • Xero expects the operating expense to revenue ratio to remain around 73% for FY25.
  • There are no changes to the forecast provided with the FY24 results.
  • For FY25, product design and development costs as a percentage of revenue are projected to increase compared to FY24.
  • Xero plans to remove between 125,000 and 175,000 long idle subscriptions in the first half of FY25.
  • Current stock recommendations include 14 buys, 3 holds, and 1 sell.
  • Comparisons are made against values reported in the company’s original disclosures.

Xero Ltd on Smartkarma

Analysts on Smartkarma, such as Hurdle Rate, have been closely covering Xero Ltd, a company in the accounting industry. In a recent blog post titled “Xero’s Price Hikes,” Hurdle Rate discusses the controversial topic of Xero’s recent pricing changes that have sparked debate within the Australian accounting sector. Hurdle Rate aims to provide specific insights into the global landscape of professional and financial services, with a focus on topics like Xero’s pricing strategies.

Hurdle Rate‘s analysis on Smartkarma delves into the implications of Xero’s pricing decisions, shedding light on the potential impact on the company and the industry as a whole. By offering a bullish perspective on Xero’s price hikes, Hurdle Rate‘s research provides valuable insights for investors looking to understand the dynamics shaping Xero Ltd‘s business strategy and market positioning.


A look at Xero Ltd Smart Scores

FactorScoreMagnitude
Value2
Dividend1
Growth5
Resilience5
Momentum4
OVERALL SMART SCORE3.4

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Analysts assessing Xero Ltd‘s long-term outlook through the Smartkarma Smart Scores paint a promising picture. With a stellar Growth score of 5 and a Resilience score of 5, the company appears primed for significant expansion while displaying a strong ability to weather economic uncertainties. Momentum is also on Xero’s side, garnering a score of 4, indicating positive market sentiment and potential for continued upward trajectory. However, challenges may lie in the Value and Dividend realms, with scores of 2 and 1 respectively, suggesting these aspects might need attention for long-term sustainability.

Overall, Xero Limited, known for its online accounting system, seems poised for growth and has demonstrated resilience in the face of market fluctuations. With a suite of financial management tools including invoicing, reporting, and expense tracking, Xero is well-positioned to capitalize on its strong Growth and Resilience scores. Investors eyeing the company should monitor how Xero addresses the Value and Dividend aspects to ensure a well-rounded investment strategy aligning with the company’s long-term vision.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

Sonic Healthcare (SHL) Earnings: FY Net Income Surpasses Estimates With A$511.1M

By | Earnings Alerts
  • Net income: A$511.1 million, beating the estimate of A$482.9 million
  • Final dividend per share: A$0.63
  • Revenue: A$8.97 billion, exceeding the estimate of A$8.87 billion
  • Ebitda: A$1.63 billion, higher than the estimate of A$1.6 billion
  • Cash generated from operations: A$1.07 billion
  • Analyst ratings: 4 buys, 8 holds, 3 sells

A look at Sonic Healthcare Smart Scores

FactorScoreMagnitude
Value3
Dividend3
Growth3
Resilience2
Momentum3
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Sonic Healthcare‘s long-term outlook appears promising across various factors. With a balanced score of 3 for Value, Dividend, Growth, and Momentum, the company shows stability and potential for growth. However, it received a slightly lower score of 2 for Resilience, indicating some room for improvement in terms of its ability to withstand economic fluctuations. Sonic Healthcare Limited, a medical diagnostics company operating in Australia, New Zealand, and Europe, offers a wide range of pathology and diagnostic imaging services to medical professionals and patients. With its solid overall Smart Scores, Sonic Healthcare may present a favorable investment option for those seeking a reliable player in the healthcare sector.

Smartkarma’s evaluation of Sonic Healthcare‘s Value, Dividend, Growth, Resilience, and Momentum scores highlights the company’s position for long-term success. With a consistent score of 3 in most areas, Sonic Healthcare demonstrates a steady performance outlook, especially in terms of value and growth potential. While the resilience score of 2 suggests room for enhancement in handling economic uncertainties, the company’s overall standing remains positive. Sonic Healthcare‘s diverse operations and comprehensive services in medical diagnostics position it well for continued growth and stability in the healthcare industry, making it a notable player to watch for investors eyeing long-term opportunities.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars